Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
Melanoma patients with BRAF mutations may benefit more from the combination of encorafenib and binimetinib, two investigational medicines, than from Zelboraf (vemurafenib) monotherapy, according to data from the first part ... Read more
An experimental cancer drug called pevonedistat appears to be quite promising against melanoma and possibly other forms of cancer, according to a recent study from the University of Virginia (UVA) School of Medicine. In ... Read more
To reach circulation and invade other organs, melanoma cells must travel from the epidermis (outer layer of skin) where there is marked absence of blood vessels, to the dermis (deeper level ... Read more
Inhibition of a long noncoding RNA called RMEL3 may help treat melanoma patients, including those with a BRAF mutation, according to a recent study developed by researchers at the University ... Read more
Patients undergoing melanoma screening and surveillance should be examined in the perianal area for melanocytic nevi, or moles, that are associated with atypical nevi elsewhere on the body, according to researchers at ... Read more
Developed by United Kingdom researchers, a new compound dubbed “mitoiron claw” can protect cells from UVA radiation in sunlight and might enhance the effects of sunscreen and skin care products that now ... Read more
Researchers at Loyola University Chicago Stritch School of Medicine have found that the combination of new immunotherapies with radiation therapy offers a promising therapeutic approach for melanoma patients. The study, “The integration ... Read more